Navigation Links
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
Date:11/11/2008

y double-blind, anti-arrhythmic, morbidity-mortality study in patients with AF. It was conducted in more than 550 sites in 37 countries and enrolled a total of 4,628 patients.

Previous results from the landmark ATHENA study have shown that dronedarone on top of standard therapy decreased the combined primary endpoint of cardiovascular hospitalization or death from any cause by a statistically significant 24 percent (p<0.001) as compared to placebo and reduced the risk of cardiovascular hospitalization by 25 percent (p<0.001). These results were achieved with a favorable safety profile.

The patients studied in ATHENA were either 75 years of age or older (with or without cardiovascular risk factor) either below 75 years of age with at least one additional cardiovascular risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40 percent). Patients with decompensated heart failure (NYHA class IV) were excluded. Patients were randomized to receive dronedarone 400 mg BID or placebo, with a maximum follow-up of 30 months.

The ATHENA study objectives were to show a potential benefit of dronedarone on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization as compared to placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalisation for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including: all adverse events, serious adverse events, adverse events leading to study drug discontinuation.

About dronedarone (Multaq(R))

Dronedarone (Multaq(R)) is an investigational treatment and the only Anti-Arrhythmic Drug (AAD) to have shown a significant reduction in morbidity and mortality in AF/AFL patients with a favourable
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
(Date:7/24/2014)... COLUMBUS, Ohio, July 24, 2014  Mettler-Toledo International Inc. ... results for 2014.  Provided below are the highlights: ... in the quarter compared with the prior year. Reported ... currency. , Net earnings per diluted share as ... second quarter of 2013. Adjusted EPS was $2.57, an ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Therapeutics (Nasdaq: FOLD ) will release its first quarter 2010 financial results ... The results announcement will be followed by a live conference call and webcast ... , , ... 5 p.m. EDT by dialing 877-303-5859 (U.S./ Canada ) or 678-224-7784 ...
... April 27 The U.S. Food and Drug Administration today approved the ... in certain adults. , , , ... ) , , , ... is intended for patients ages 18 and older whose severe and persistent asthma ...
Cached Medicine Technology:Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010 2FDA Approves New Device for Adults with Severe and Persistent Asthma 2FDA Approves New Device for Adults with Severe and Persistent Asthma 3
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... Outlook to 2020” provides company shares and distribution ... and global corporate-level profiles of the key market ... to the Laryngoscopes market wherever available. , The ... market forecast models. Rsearcher uses epidemiology and capital ...
(Date:7/25/2014)... 2014 (HealthDay News) -- Although cervical cancers are declining ... to human papillomavirus (HPV) are increasing, a new study ... base of the tongue and tonsils have increased over ... younger than 45, the Canadian researchers report. "The ... younger men and of anal cancer among younger women ...
(Date:7/25/2014)... July 25, 2014 The Europe Cyber ... market in Europe with analysis and forecast of revenue. ... billion in 2014 to $19.07 billion by 2019, at ... Browse through the TOC of the Europe Cyber Security ... analysis provided. It also provides a glimpse of the ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The American ... new volunteer network “ABTA CommYOUnity™” during its annual patient ... pivotal time for the brain tumor community as we ... patient and caregiver support services and funding brain tumor ... are passionate about brain tumor awareness and getting our ...
(Date:7/25/2014)... July 25, 2014 Today, nearly 700,000 people ... yet, when it comes to pinpointing causes or risk factors, ... don’t know who, we don’t know when, and we don’t ... MNA, president & CEO, American Brain Tumor Association. “It’s frustrating ... Brain Tumor Association funds research to pursue answers to these ...
Breaking Medicine News(10 mins):Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 2Health News:Brain Tumor Causes and Risk Factors Elude Scientists 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 4
... is being developed that will create a calendar-like printout ... of Georgia physical therapist and associate dean, who wanted ... ,Multiple prescriptions can be confusing: knowing which pill is ... have special instructions. ,'The idea came ...
... excessive dandruff and it could be treated as an early ... // ,Barry Stevens, founder of the London Trichology Society, ... common among AIDS patients. ,'Seborrhoeic Dermatitis among HIV-positive ... percent among general population,' he said. ,'Though a ...
... Society (WHS) and Blackwell Publishing are excited to announce ... Wounds in a special issue of Wound Repair and ... ,Because of continued interest by the WHS ... Foundation, a proposal was developed to establish guidelines for ...
... this holiday season? It’s one of the biggest fashion trends this ... back, neck and shoulder pain, headaches and possibly even arthritis. // ... headaches and what I usually do is look for their purse ... on the medical staff at Baylor Medical Center at Garland. ...
... a study that affirms the role of partners or ... ,Publishing results in the January issue of Archives of Dermatology, ... for skin examination sessions are bound to take the sessions ... translates to reduced risks of developing the dreaded melanoma or ...
... met his Waterloo twice, the second time proving fatal, at ... from US, Switzerland and Canada have put to rest a ... of the French conqueror. ,The most recent theory, ... of Napoleons’ hair was that the ruler’s death was due ...
Cached Medicine News:Health News:New Software to Help Patients 2Health News:Pair Up-Prevent Melanoma 2Health News:Mighty Conqueror Felled by Stomach Cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: